Rapid antiretroviral therapy initiation in patients with advanced HIV disease: 6-month outcomes of an observational cohort evaluation in Lesotho.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 22 12 2021
accepted: 26 09 2023
medline: 2 11 2023
pubmed: 11 10 2023
entrez: 11 10 2023
Statut: epublish

Résumé

For adults and adolescents, the World Health Organization defines advanced HIV disease (AHD) as a CD4 (cluster of differentiation 4) count of <200 cells/mm3 or a clinical stage 3 or 4 event. We describe clinical outcomes in a cohort of AHD patients at two regional hospitals in Lesotho. From November 2018-June 2019, we prospectively enrolled eligible patients (≥15 years) not on antiretroviral therapy (ART) presenting with WHO-defined AHD into a differentiated model of care for AHD (including rapid ART initiation) and followed them for six months. All patients received Tuberculosis (TB) symptom screening with further diagnostic testing; serum cryptococcal antigen (CrAg) screening was done for CD4 <100 cells/mm3 or WHO clinical stage 3 or 4. Medical record data were abstracted using visit checklist forms. Categorical and continuous variables were summarized using frequencies, percentages, and means, respectively. Kaplan-Meier was used to estimate survival. Of 537 HIV-positive patients screened, 150 (27.9%) had AHD of which 109 were enrolled. Mean age was 38 years and 62 (56.9%) were men. At initial clinic visit, 8 (7.3%) were already on treatment and 33% (36/109) had presumptive TB per symptom screening. Among 39/109 (40.2%) patients screened for CrAg at initial visit, five (12.8%) were CrAg-positive. Among 109 enrolled, 77 (70.6%) initiated ART at their initial clinic visit, while 32 delayed ART initiation (median delay: 14 days). Of the 109 participants enrolled, 76 (69.7%) completed the 6-month follow-up, 17 (15.6%) were lost to follow-up, 5 (4.6%) transferred to other health facilities and 11 (10.1%) died. The 6-month survival was 87.4%; among 74 patients with a viral load result, 6-month viral suppression (<1,000 copies/ml) was 85.1%. Our study found that even after the implementation of Test and Treat of ART in 2016 in Lesotho, over 25% of patients screened had AHD. Patients with AHD had a high prevalence of TB and CrAg positivity, underscoring the need to assess for AHD and rapidly initiate ART within a package of AHD care for optimal patient outcomes.

Identifiants

pubmed: 37819941
doi: 10.1371/journal.pone.0292660
pii: PONE-D-21-40374
pmc: PMC10566720
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0292660

Subventions

Organisme : PEPFAR
Pays : United States

Informations de copyright

Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2020 Jun 25;15(6):e0230205
pubmed: 32584821
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117
pubmed: 29514238
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139
pubmed: 29514234
BMC Infect Dis. 2022 Aug 25;22(1):706
pubmed: 36008786
J Int AIDS Soc. 2020 Jul;23(7):e25546
pubmed: 32640106
Lancet HIV. 2015 Oct;2(10):e438-44
pubmed: 26423651
Afr Health Sci. 2016 Jun;16(2):588-95
pubmed: 27605976
Front Public Health. 2019 Oct 24;7:306
pubmed: 31709218
Clin Infect Dis. 2020 Dec 3;71(9):2500-2501
pubmed: 32369101
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219847199
pubmed: 31104543
J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25530
pubmed: 32589367
Clin Infect Dis. 2012 Feb 1;54(3):424-33
pubmed: 22095568
PLoS Med. 2014 Sep 09;11(9):e1001718
pubmed: 25203931
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S118-S125
pubmed: 29514233
Curr HIV/AIDS Rep. 2013 Sep;10(3):254-63
pubmed: 23715897
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
Immunol Rev. 2013 Jul;254(1):343-54
pubmed: 23772630
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):e5-e11
pubmed: 25118796
J Virus Erad. 2018 Nov 15;4(Suppl 2):1-4
pubmed: 30515307
N Engl J Med. 2017 Jul 20;377(3):233-245
pubmed: 28723333
J Acquir Immune Defic Syndr. 2013 May 1;63(1):142-5
pubmed: 23364513
Lancet. 2016 Mar 19;387(10024):1198-209
pubmed: 27025337
Trop Med Int Health. 2013 Apr;18(4):495-503
pubmed: 23368667
PLoS One. 2019 Apr 10;14(4):e0214739
pubmed: 30969987
Lancet. 2015 May 30;385(9983):2173-82
pubmed: 25765698
J Health Care Poor Underserved. 2013 Feb;24(1):359-83
pubmed: 23377739
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Lancet HIV. 2020 Mar;7(3):e193-e200
pubmed: 32035041

Auteurs

Appolinaire Tiam (A)

Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, United States of America.

Heather Paulin (H)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Rhoderick Machekano (R)

Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, United States of America.

Ikwo Oboho (I)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Elfriede Agyemang (E)

Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Fred Asiimwe Mugyenyi (FA)

Centers for Disease Control and Prevention, Maseru, Lesotho.

Llang Maama-Maime (L)

Ministry of Health Lesotho, Maseru, Lesotho.

Yohannes Mengistu (Y)

Centers for Disease Control and Prevention, Maseru, Lesotho.

Tsitsi Chatora (T)

Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho.

More Mungati (M)

Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho.

Majoalane Mokone (M)

Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho.

Tsietso Mots'oane (T)

Ministry of Health Lesotho, Maseru, Lesotho.

Annah Masheane (A)

Ministry of Health Lesotho, Maseru, Lesotho.

Vincent Tukei (V)

Elizabeth Glaser Pediatric AIDS Foundation, Maseru, Lesotho.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH